Barclays’s Myovant Sciences Ltd. MYOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-180,840
| Closed | -$4.88M | – | 5513 |
|
|
2022
Q4 | $4.88M | Buy |
180,840
+80,746
| +81% | +$2.12M | ﹤0.01% | 1654 |
|
|
2022
Q3 | $1.8M | Buy |
100,094
+86,093
| +615% | +$1.37M | ﹤0.01% | 1825 |
|
|
2022
Q2 | $174K | Sell |
14,001
-23,171
| -62% | -$256K | ﹤0.01% | 3515 |
|
|
2022
Q1 | $495K | Buy |
+37,172
| New | +$498K | ﹤0.01% | 2917 |
|
|
2021
Q4 | – | Sell |
-5,147
| Closed | -$116K | – | 4891 |
|
|
2021
Q3 | $116K | Buy |
5,147
+3,794
| +280% | +$83.3K | ﹤0.01% | 3850 |
|
|
2021
Q2 | $31K | Sell |
1,353
-17,183
| -93% | -$362K | ﹤0.01% | 4361 |
|
|
2021
Q1 | $381K | Sell |
18,536
-27,964
| -60% | -$637K | ﹤0.01% | 3350 |
|
|
2020
Q4 | $1.28M | Sell |
46,500
-24,700
| -35% | -$481K | ﹤0.01% | 2585 |
|
|
2020
Q3 | $1M | Sell |
71,200
-8,200
| -10% | -$153K | ﹤0.01% | 2700 |
|
|
2020
Q2 | $1.64M | Buy |
+79,400
| New | +$1.08M | ﹤0.01% | 2311 |
|
|
2020
Q1 | – | Sell |
-26,300
| Closed | -$408K | – | 6596 |
|
|
2019
Q4 | $408K | Buy |
26,300
+14,983
| +132% | +$151K | ﹤0.01% | 4471 |
|
|
2019
Q3 | $59K | Buy |
11,317
+2,234
| +25% | +$16.6K | ﹤0.01% | 5822 |
|
|
2019
Q2 | $82K | Buy |
+9,083
| New | +$135K | ﹤0.01% | 5839 |
|
|
2017
Q3 | – | Sell |
-10,877
| Closed | -$127K | – | 7120 |
|
|
2017
Q2 | $127K | Buy |
10,877
+10,734
| +7,506% | +$133K | ﹤0.01% | 4748 |
|
|
2017
Q1 | $1K | Sell |
143
-57
| -29% | -$653 | ﹤0.01% | 6663 |
|
|
2016
Q4 | $2K | Buy |
+200
| New | +$2.32K | ﹤0.01% | 6398 |
|
Other funds holding MYOV
Barclays's MYOV Position: Q1 2023 in Review
Barclays sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 180,840 shares — an estimated $4.88M sold.
Barclays first reported a position in MYOV in Q4 2016 and held it in 16 quarters. The position peaked at $4.88M in Q4 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.
- Barclays reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
- Barclays sold 180,840 Myovant Sciences Ltd. shares in Q1 2023, an estimated $4.88M.
- Barclays first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 16 quarters.
- Barclays's Myovant Sciences Ltd. position peaked at $4.88M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.
Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.